Clinical Trials
3 trialsNCT04421222 2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1 Terminated
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed